|
Analysts See More FDA Concerns With Constipation Drugs Post-CRL
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives